Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation

BACKGROUND: Previous studies have demonstrated the combination of epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) and other antitumor agents may delay drug resistance. In this study, we retrospectively reviewed the efficacy and safety of first‐line concurrent EGFR‐TKIs and...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ziyi, Hao, Xuezhi, Lin, Lin, Li, Junling, Xing, Puyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365005/
https://www.ncbi.nlm.nih.gov/pubmed/34180588
http://dx.doi.org/10.1111/1759-7714.14057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365005/
https://www.ncbi.nlm.nih.gov/pubmed/34180588
http://dx.doi.org/10.1111/1759-7714.14057

Ejemplares similares